Cite
MLA Citation
A. Wollenberg et al.. “Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2).” British journal of dermatology, vol. 184, 2021, pp. 437–449. http://access.bl.uk/ark:/81055/vdc_100123372263.0x00005e